Wealthfront Advisers
TMO icon

Wealthfront Advisers’s Thermo Fisher Scientific TMO Stock Holding History

Wealthfront Advisers’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
25,833
-6,435
-20% -$3.09M 0.02% 222
2026
Q1 		$15.9M Buy
32,268
+4,145
+15% +$2.25M 0.03% 176
2025
Q4 		$16.3M Buy
28,123
+5,738
+26% +$3.24M 0.04% 163
2025
Q3 		$10.9M Buy
22,385
+6,954
+45% +$3.24M 0.03% 225
2025
Q2 		$6.26M Sell
15,431
-7,068
-31% -$2.96M 0.02% 328
2025
Q1 		$11.2M Sell
22,499
-26
-0.1% -$14.1K 0.03% 180
2024
Q4 		$11.7M Buy
22,525
+945
+4% +$520K 0.03% 159
2024
Q3 		$13.3M Buy
21,580
+346
+2% +$205K 0.04% 134
2024
Q2 		$11.7M Buy
21,234
+38
+0.2% +$21.8K 0.04% 133
2024
Q1 		$12.3M Buy
21,196
+1,374
+7% +$771K 0.04% 127
2023
Q4 		$10.5M Sell
19,822
-1,390
-7% -$673K 0.04% 131
2023
Q3 		$10.7M Buy
21,212
+817
+4% +$435K 0.05% 115
2023
Q2 		$10.6M Sell
20,395
-7,095
-26% -$3.83M 0.05% 120
2023
Q1 		$15.8M Buy
27,490
+835
+3% +$471K 0.07% 72
2022
Q4 		$14.7M Sell
26,655
-9,068
-25% -$4.81M 0.07% 75
2022
Q3 		$18.1M Buy
35,723
+1,522
+4% +$852K 0.1% 58
2022
Q2 		$18.6M Sell
34,201
-1,777
-5% -$978K 0.09% 59
2022
Q1 		$21.3M Buy
35,978
+711
+2% +$408K 0.09% 52
2021
Q4 		$23.5M Buy
35,267
+5,500
+18% +$3.43M 0.1% 45
2021
Q3 		$17M Buy
29,767
+7,690
+35% +$4.22M 0.08% 48
2021
Q2 		$11.1M Buy
22,077
+572
+3% +$270K 0.05% 64
2021
Q1 		$9.81M Buy
21,505
+2,893
+16% +$1.38M 0.05% 66
2020
Q4 		$8.67M Buy
18,612
+1,314
+8% +$616K 0.05% 64
2020
Q3 		$7.64M Buy
17,298
+786
+5% +$325K 0.05% 69
2020
Q2 		$5.98M Buy
16,512
+1,792
+12% +$601K 0.05% 74
2020
Q1 		$4.17M Buy
14,720
+3,259
+28% +$1.03M 0.04% 80
2019
Q4 		$3.72M Buy
11,461
+1,213
+12% +$368K 0.03% 104
2019
Q3 		$2.98M Buy
10,248
+635
+7% +$182K 0.03% 115
2019
Q2 		$2.82M Buy
9,613
+478
+5% +$132K 0.02% 116
2019
Q1 		$2.5M Buy
9,135
+1,902
+26% +$473K 0.02% 121
2018
Q4 		$1.62M Buy
+7,233
New +$1.7M 0.02% 157

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wealthfront Advisers's TMO Position: Q2 2026 in Review

Wealthfront Advisers reduced its Thermo Fisher Scientific (TMO) stake by 20% in Q2 2026, selling an estimated $3.09M and leaving 25,833 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #222.

Wealthfront Advisers first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. The position peaked at $23.5M in Q4 2021. 2,022 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Wealthfront Advisers held 25,833 shares of Thermo Fisher Scientific worth $13M as of Q2 2026.
  • Wealthfront Advisers sold 6,435 Thermo Fisher Scientific shares in Q2 2026, an estimated $3.09M.
  • Thermo Fisher Scientific made up 0.02% of Wealthfront Advisers's portfolio in Q2 2026, its #222 holding.
  • Wealthfront Advisers first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
  • Wealthfront Advisers's Thermo Fisher Scientific position peaked at $23.5M in Q4 2021.
  • 2,022 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.